title: Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women.
abstract: OBJECTIVE
  To investigate the effects of raloxifene on the insulin sensitivity and lipid profile in insulin-sensitive and insulin-resistant postmenopausal women.
  
  
  METHODS
  This placebo-controlled, double-blind, randomized study involved 64 postmenopausal women aged between 45 and 55 years. All subjects were screened with the insulin resistance homeostasis model assessment (IR-HOMA) and those patients in the lowest quartile (n = 16) were assigned as insulin sensitive and those in the highest quartile as insulin resistant (n = 16). Patients in both groups received either raloxifene hydrochloride (60 mg/day) or a placebo for a period of 12 weeks. Insulin sensitivity, the serum lipid profile and anthropometric measurements were established before and after therapy.
  
  
  RESULTS
  Women with the highest IR-HOMA scores were associated with a significantly higher weight, body mass index, waist and waist-to-hip ratio (p < 0.05). Raloxifene significantly reduced the IR-HOMA scores from 5.76 ± 2.91 to 1.93 ± 0.96 (p = 0.02) and modified the lipid profile in insulin-resistant patients when compared with the placebo group and those patients receiving raloxifene in the insulin-sensitive group.
  
  
  CONCLUSIONS
  Raloxifene reduced insulin resistance and modified the lipid profile in insulin-resistant postmenopausal women.
authors: Cardiovascular Research Unit, Physiology Department, University Center of Health Sciences, Guadalajara University, México. fgroverp@hotmail.com
authors: Fernando
authors: F
authors: Grover-Páez
authors: Ana Bertha
authors: AB
authors: Zavalza-Gómez
authors: Roberto
authors: R
authors: Anaya-Prado
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause / Q000187:drug effects / Q000378:metabolism; D011236:Prediabetic State / Q000188:drug therapy / Q000378:metabolism; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage*
chemical_list: D007328:Insulin; D008055:Lipids; D010919:Placebos; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride